SEC Form 4 research
| Issuer | Protalix BioTherapeutics, Inc. |
|---|---|
| Tickers | ORTX, PLX, ORTX.OB |
| Reporting owners | 40 |
| Officers and directors | 11 |
| Last public filing | 2026-09-09 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-09-09 | 2026-09-03 | Schwartz Aharon | A | 8,500 | $0 | Not reported |
| 2026-09-09 | 2026-09-03 | Schwartz Aharon | A | 17,000 | $0 | Not reported |
| 2026-09-04 | 2026-09-03 | Elze Christian | A | 8,500 | $0 | Not reported |
| 2026-09-04 | 2026-09-03 | Elze Christian | A | 17,000 | $0 | Not reported |
| 2026-09-04 | 2026-09-03 | Ben Zvi Shmuel | A | 8,500 | $0 | Not reported |
| 2026-09-04 | 2026-09-03 | Ben Zvi Shmuel | A | 17,000 | $0 | Not reported |
| 2026-09-04 | 2026-09-03 | Forster Eliot | A | 8,500 | $0 | Not reported |
| 2026-09-04 | 2026-09-03 | Forster Eliot | A | 17,000 | $0 | Not reported |
| 2026-09-04 | 2026-09-03 | Bashan Dror | A | 160,000 | $0 | Not reported |
| 2026-09-04 | 2026-09-03 | Bashan Dror | A | 320,000 | $0 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.